STERIS plc’s STE continues to thrive, fueled by strong procedure volume growth, favorable pricing and market share gains. The company is seeing early signs of increased bioprocessing demand ...
STERIS plc reported its third-quarter earnings for fiscal year 2024, revealing a slight miss on earnings per share (EPS) but a notable revenue beat. The company posted an EPS of $2.32, just shy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback